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Abstract
Background: An arg120gly (R120G) missense mutation in HSPB5 (a-b-crystallin ), which belongs to the small heat shock
protein (HSP) family, causes desmin-related cardiomyopathy (DRM), a muscle disease that is characterized by the formation
of inclusion bodies, which can contain pre-amyloid oligomer intermediates (amyloid oligomer). While we have shown that
small HSPs can directly interrupt amyloid oligomer formation, the in vivo protective effects of the small HSPs on the
development of DRM is still uncertain.
Methodology/Principal Findings: In order to extend the previous in vitro findings to in vivo, we used geranylger-
anylacetone (GGA), a potent HSP inducer. Oral administration of GGA resulted not only in up-regulation of the expression
level of HSPB8 and HSPB1 in the heart of HSPB5 R120G transgenic (R120G TG) mice, but also reduced amyloid oligomer
levels and aggregates. Furthermore, R120G TG mice treated with GGA exhibited decreased heart size and less interstitial
fibrosis, as well as improved cardiac function and survival compared to untreated R120G TG mice. To address possible
mechanism(s) for these beneficial effects, cardiac-specific transgenic mice expressing HSPB8 were generated.
Overexpression of HSPB8 led to a reduction in amyloid oligomer and aggregate formation, resulting in improved cardiac
function and survival. Treatment with GGA as well as the overexpression of HSPB8 also inhibited cytochrome c release from
mitochondria, activation of caspase-3 and TUNEL-positive cardiomyocyte death in the R120G TG mice.
Conclusions/Significance: Expression of small HSPs such as HSPB8 and HSPB1 by GGA may be a new therapeutic strategy
for patients with DRM.
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Introduction
Many systemic and neurodegenerative disorders whose etiologies
arelinkedtomisfoldedorunfoldedproteinsarecharacterized bythe
accumulation of intracellular or extracellular protein deposits or
aggregates known as aggresomes [1,2]. As well as neurodegener-
ative pathologies and other age-related illnesses, many recent
publications suggest that the accumulation of misfolded or unfolded
proteins contributes to a number of cardiovascular diseases such as
cardiomyopathy, myocardial infarction and heart failure [3,4,5].
Heat shock proteins (HSPs) are present to prevent the accumulation
of the misfolded or unfolded proteins in the cells. HSPs can protect
other proteins as molecular chaperones against misfolding by
stabilizing them, and usually remove them when misfolded [6].
Lower levels of HSPs, or reduced efficacy of molecular chaperones
could be associated with cardiovascular disease and aspects of
ageing [7,8]. It is also known that mutations or other changes in the
chaperone proteins themselves cause them to actually promote
misfolding, rather than guard against it [9]. This implies that
cellular levels of HSPs play a critical role in progression and severity
of disease linked to misfolded or unfolded proteins.
The small HSPs, such as HSPB5 (alpha-beta-crystallin), HSPB8
(HSP22 or H11 kinase) and HSPB1 (HSP25), share sequence
similarity within the a-crystallin domain but exhibit different
patterns of gene expression, transcriptional regulation, and sub-
cellular localization [10]. The chaperone-like activity of small
HSPs, which are classified according to their ability to prevent
protein aggregation and/or restore the biological activity of the
substrates, is widely believed to be a protective mechanism for
protein misfolding and denaturation triggered by noxious
environmental stimuli, such as hyperthermic stress, heavy metals,
ischemic injury, and some genetic diseases [2,10,11].
The arg120gly (R120G) missense mutation in HSPB5 can cause
desmin-related cardiomyopathy (DRM) [12]. This disease, which
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and desmin, is a misfolded protein-related disease and can be
recapitulated in transgenic (TG) mice by expressing the mutant
HSPB5 R120G protein specifically in the heart [9]. We showed
that HSPB5 R120G caused perinuclear aggresome formation and
that these aggresomes contained pre-amyloid oligomer intermedi-
ates (amyloid oligomer) [3]. These results suggest that DRM
caused by the HSPB5 mutation is a subclass of aggresomal and
amyloid-related diseases [3]. Furthermore, using a cardiac-specific
inducible TG system [13], we found that continuous expression of
the mutant protein is necessary for sustaining the high concentra-
tions of the amyloid oligomer that correlate with depressed cardiac
function as well as premature lethality [14]. These results indicate
that HSPB5-DRM is at least partially reversible and that the
amyloid oligomer is critical for aspects of morbidity and mortality
characteristic of DRM [14].
In our previous study, we showed that recombinant HSPB8 or
HSPB1 protein could directly interrupt HSPB5 R120G-mediated
amyloid oligomer formation although amyloid oligomer is still
present in the mixture of wild-type (WT) HSPB5 and mutant
HSPB5 R120G [15]. This interruption by HSPB1 and HSPB8
was confirmed in a cardiomyocyte-based study using an adenoviral
vector system. Blockade of amyloid oligomer formation by HSPB1
and HSPB8 led to the recovery of ubiquitin proteasomal activity
and cellular viability. These results imply that blockade of the
amyloid oligomer formation by small HSPs may be a new
therapeutic strategy for treating patients with DRM as well as
other types of amyloid-based degenerative diseases. While we have
shown that HSPB1 and HSPB8 can directly interrupt amyloid
oligomer formation caused by HSPB5 R120G and restore cellular
viability in cardiomyocytes expressing HSPB5 R120G, the in vivo
protective effects of the small HSPs on the development of DRM
remain unproven.
In the present study, we show that geranylgeranylacetone
(GGA), a nontoxic antiulcer drug and inducer of small HSPs [16],
can induce expression of HSPB8 and HSPB1 and reduce the
formation of amyloid oligomers as well as insoluble aggregates in
HSPB5 R120G TG mice. GGA led to reduction in heart size and
inhibition of interstitial fibrosis, and recovery of cardiac function as
well as improved survival. Cardiac-specific TG mice expressing
HSPB8 also inhibit the progression of cardiomyopathy in the
R120G TG mice, suggesting that the induction of HSPB8 may
play a role in inhibiting the development of DRM. Together, these
results indicate that induction of small HSPs is beneficial in the
treatment of DRM.
Materials and Methods
Trangenic mice
Male mice with cardiac-specific overexpression of wild-type
HSPB5 (WT TG) or mutant HSPB5 containing the R120G
mutation (R120G TG), driven by the a-myosin heavy chain
promoter, have been described [3]. To generate mice with
cardiac-specific inducible overexpression of HSPB8, HSPB8
cDNA was inserted into a modified myosin promoter cassette as
described previously[13,15] and generated HSPB8 TG mice. The
responder HSPB8 mice were crossed with the tetracycline-
controlled transcriptional activator (tTA) TG mice to generate
the tTA/HSPB8 double TG (tTA/HSPB8 TG) mice [13,14]. The
TG mice were identified by PCR analysis of genomic DNA
isolated from tail tips. The genetic background of the responder
HSPB8 mice used for all experiments was a C57BL/6Cr Slc (SLC,
Shizuoka, Japan). The TG mice such as WT TG, R120G TG and
tTA TG mice was backcrossed with a C57BL/6Cr Slc mouse
more than 8 times, and maintained on a C57BL/6Cr Slc
background. Animals were housed in microisolator cages in a
pathogen-free barrier facility. All experimentation was performed
under approved institutional guidelines. Non-transgenic (NTG)
littermates animals with the same genetic background were always
used as controls for comparison. Animals were housed in
microisolator cages in a pathogen-free barrier facility. All
experiments were performed under the approved guidelines for
the Care and Use of Laboratory Animals of the National Research
Institute for Chile Health and Development.
Cardiomyocyte cultures and adenovirus infection
After isolation of rat neonatal cardiomyocytes, cells were grown
on glass slides coated with a gelatin as described previously [3,15].
Replication-deficient recombinant adenoviruses were made using
an AdEasy system [3,15]. The cells were normally infected at a
multiplicity of infection of 10 for each virus except where indicated.
Experimental design and protocol for drug treatment in
in vitro and in vivo
GGA was purchased from Eisai, Inc. (Tokyo, Japan). For the
study with cardiomyocytes, GGA was dissolved in ethanol, and
ethanol alone was used as the vehicle (0 nM of GGA). After 24-hr
isolation of the cardiomyocytes, GGA was added into the culture
medium and sustained until the end of the experiments. Twenty-
four hr after GGA treatment, an adenoviral vector containing
HSPB5 R120G was infected into the cardiomyocytes. Forty-eight
hours after infection, Western blotting, cellular viability assay and
immunohistochemistry were performed.
For oral administration in mice, the GGA granules were mixed
with powdered rodent chow at concentrations of 0.25%, 0.5%, 1%,
a n d2 % ,a n de a c hp o w d e r e dro d e n tc h o wc o n t a i n in gGG Aw a sg i v e n
to the mice. All mice had unlimited access to food and water. After
TG mice were genotyped by analysis of their tail tips, HSPB5 R120G
TG mice were given GGA starting at 4 weeks of age and continuing
for 41 weeks. By the time GGA was started, obvious aggresomes
containing HSPB5 were already visible in the HSPB5 R120G TG
mouse hearts [9]. Thus, we started administering GGA at an early
stage of disease in the DRM. Western blotting, morphological
analysis, immunohistochemistry and echocardiography were per-
formed on the mice at 30 weeks of age as described above.
To evaluate the effect of HSPB8 on the development of the cardiac
disease caused by the HSPB5 R120G mutation, HSPB5 R120G TG
mice were crossbred with tTA/HSPB8 double transgenic (tTA/
HSPB8 TG) mice to generate tTA/HSPB8/R120G triple transgenic
mice (Triple TG). Multiple analyses such as Western blotting,
morphology and echocardiography were performed on NTG,
R120G TG, tTA/HSPB8 TG, and triple TG mice at 30 weeks of
age. In some sets of experiments, we analyzed the triple TG mice
treated with doxycycline as described previously [13,14]. In these
cases, doxycycline treatment was started in the triple TG mice at 4
weeks of age and continued until 30 weeks of age.
Immunohistochemistry
Immunohistochemical analyses were performed as described
[3,14,15]. Alexa488-conjugated anti-rabbit, Alexa568-conjugated
anti-mouse antibodies, and phalloidin-Alexa 488 were from
Molecular Probes (Eugene, OR). Anti-HSPB5 antibody (SPA-
223) was from Assay Designs, Inc. (Ann Arbor, MI), anti-troponin
I (TnI) antibody (MAB1691) was from Chemicon International
(Temecula, CA) and anti-HSPB8 antibody was from Imgenex (San
Diego, CA). The anti-oligomer antibody (A-11) was generated and
used as described previously [3]. The cellular viability was
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zolium bromide (MTT) assay [15]. Image J 1.36b was used to
quantify the immunofluorescent intensity. The results from 30–50
cells were averaged for cohort comparison. The area stained with
the oligomer antibody was defined, and the average pixel intensity
of the cardiomyocyte was determined for comparison [15].
Miscellaneous methods
Sample preparation for Western blotting, gel preparation, and
electrophoretic conditions have been described [14,17,18].
Western blot analyses were performed with the use of anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Chemicon
International, Temecula, CA), anti-HSP70 (Ab-1, Merck Co. Inc.,
Whitehouse Station, NJ), anti-HSP B5 antibody (SPA-223, Assay
Designs Inc., Ann Arbor, MI), anti-HSP B1 (SPA-801, Assay
Designs Inc., Ann Arbor, MI), anti-HSP B8 antibody (Imgenex,
San Diego, CA), anti-heat shock factor (HSF)1(SPA-901, Assay
Designs Inc., Ann Arbor, MI), anti-Cytochrome C (BD Bioscience,
CA), anti-voltage dependent anion channel (VDAC) (EMD
Chemicals Inc., Gibbstown, NJ), and anti-activated caspase-3
(Abcam Inc., Cambridge, MA). The band intensity in the
immunoblot was semi-quantified using Image J1.36b. The filter
assay for the detection of the aggregates was performed as
described previously [3,14]. The aggregate fraction on the
membrane was detected with an anti-HSP B5 antibody. TdT-
mediated dUTP-biotin Nick End Labeling (TUNEL) staining was
carried out using an in situ cell death detection kit, TMR Red
(Roche, Basel, Switzerland), following the manufacturer’s instruc-
tions as described previously [18]. The number of DAPI-labeled
nuclei was counted and compared to the number of TUNEL-
positive cells [18]. Trichrome staining was performed as described
[17]. Trichrome staining was performed as described [17].
Figure 1. Induction of small HSPs by GGA in neonatal rat cardiomyocytes. (A) Western blot analysis. GGA induced the expression levels of
small HSPs in a dose-dependent manner. (B) Quantitative analysis of small HSP expression (n=4). Values are the -fold increase relative to
cardiomyocyte cultures treated with vehicle (0 nM of GGA) whose values are arbitrarily set to 1. * p,0.05, ** p,0.01 and *** p,0.001 vs. 0 nM of
GGA. (C) Representative pictures of immunohistochemical analyses in the HSPB5 R120G-infected cardiomyocytes. Cardiomyocytes were infected with
the adenovirus vector containing the wild-type HSPB5 (WT) or mutant HSPB5 R120G (R120G). An amyloid oligomer (green) was detected by the anti-
oligomer antibody as described in Materials and Methods. Nuclei were stained with DAPI. (D) Quantitative analysis of the amyloid oligomer. Amyloid
oligomer levels were measured by fluorescence intensity (n=4). *** p,0.001 vs. cardiomyocytes infected with WT, and ### p,0.001 vs.
cardiomyocytes infected with R120G. (E) Protective effects of GGA on the cellular viability of the HSPB5 R120G-infected cardiomyocytes. Cellular
viability was determined by the MTT assay. Values are the -fold increase relative to untreated cardiomyocyte cultures whose values are arbitrarily set
to 1 (n=6). *** p,0.001 vs. untreated cardiomyocytes (UN), ### p,0.001 vs. cardiomyocytes infected with WT, and aa p,0.01 vs. cardiomyocytes
infected with R120G.
doi:10.1371/journal.pone.0005351.g001
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Echocardiography was performed as described previously [19].
Mice were anesthetized with an intraperitoneal injection of
30 mg/kg pentobarbital (Sigma, St. Louis, MO). After anesthesia,
the left hemithorax of the mouse was shaved. The animals were
pre-warmed with a panel heater to maintain their rectal
temperature at 37uC during the determination of cardiac
parameters by echocardiography. Transthoracic echocardiogra-
phy was performed by using ProSound 5500R (Aloka, Tokyo,
Japan) with a 13-MHz linear transducer for mice in a phased array
format, which offers 0.35-mm lateral resolution and 0.25-mm axial
resolution, real time digital acquisition, storage, and review
capabilities. The heart was first imaged in the two-dimensional
mode in the parasternal long-axis view. From this view, an M-
mode cursor was positioned perpendicular to the interventricular
septum and posterior wall of the left ventricle at the level of the
papillary muscles. Chamber dimensions were determined by the
M-mode tracings. In contrast, a two-dimensional short-axis view of
the mid-left ventricle at the chordal level was assessed by the B-
mode tracings. Wall thickness was determined from this
dimensional short-axis view. Each cardiac parameters was
calculated from the echocardiogram as described previously [19].
Statistics
Data are expressed as the mean6standard error. Statistical
analysis was performed using the unpaired Student’s t-test and
one-way or two-way ANOVA followed by a post hoc comparison
with Fisher’s PLSD using Statview version 5.0 software (Concepts,
Inc., Berkeley, CA, USA). Differences between groups were
considered statistically significant at the level of p,0.05.
Results
GGA induces small HSPs in cardiomyocytes
Effects of GGA on the expression level of small HSPs were
evaluated in the isolated neonatal rat cardiomyocytes. While GGA
increased the expression levels of HSPB8 and HSPB1 as well as
HSP70 in a dose-dependent manner, no induction of HSPB5 was
observed (Figure 1A and B). These results suggest that GGA can
induce some stress proteins in the cardiomyocytes [16,20]. Since
we have found that HSPB8 and HSPB1 can reduce the amyloid
oligomer toxicity generated by HSPB5 R120G [15], we analyzed
the effect of GGA on generating amyloid oligomers caused by
HSPB5 R120G expression (Figure 1C and D). As expected,
amyloid oligomer levels increased (Figure 1C and D), reducing
Figure 2. In vivo enhancement of small HSP induction by GGA. (A) Representative pictures of Western blot analysis of the R120G TG mouse
heart. (B) Quantitative analysis of the small HSP expression levels (n=4 mice). Values are the -fold increase relative to those in NTG mice whose values
are arbitrarily set to 1. *** p,0.001 vs. NTG. Values of wild-type HSPB5 TG mice (WT TG) are also shown as a control. (C) Diagram of the protocols. NTG
and HSPB5 R120G TG mice at 4 weeks of age were administered GGA. Western blotting, morphological analysis, immunohistochemistry and
echocardiography were performed on the mice at 30 weeks of age (arrow). (D) Representative pictures of Western blot analysis of hearts from R120G
TG mice treated with GGA. GGA was administrated in R120G TG mice from 4 weeks until 30 weeks of age. (E) Quantitative analysis of the small HSP
expression levels (n=4–5 mice). Values are the -fold increase relative to those in NTG mice whose values are arbitrarily set to 1. * p,0.05, ** p,0.01
and *** p,0.001 vs. 0% GGA.
doi:10.1371/journal.pone.0005351.g002
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increase in amyloid oligomer formation and increased viability
(Figure 1C, D and E), suggesting that GGA is protective against
the cellular toxicity induced by HSPB5 R120G.
Effect of GGA on stress protein levels in HSPB5 R120G TG
mouse hearts
In order to extend these in vitro data, the in vivo effects of GGA
were examined in the mouse hearts. We first analyzed expression
levels of small HSPs in the hearts from R120G TG mice at 30 weeks
of age (Figure 2A and B). The expression level of HSPB5 was similar
between R120G TG and WT TG mice as described previously [9].
Although the expression levels of HSPB5 in the WT and R120G
hearts were similar, HSPB8, HSPB1 and HSP70 were up-regulated
in the hearts from R120G TG mice as compared with those of
HSPB5 WT TG and NTG mice (Figure 2A and B). There were no
differences in HSPB8, HSPB1 and HSP70 levels between WT TG
andNTGmice,althoughHSPB5wasoverexpressedinWTTGmice
(Figure 2A and B). Up-regulation of the small HSPs is probably due
to a cellular adaptation in response to stress caused by the mutant
HSPB5 R120G protein [3]. We then examined the long-term effects
of GGA on small HSP expression in the NTG and HSPB5 R120G
TG mice (Figure 2C–E). HSPB5 R120G TG mice were given GGA
starting at 4 weeks of age and continuing for 41 weeks (Figure 2C).
Westernblotting,morphologicalanalysis,immunohistochemistryand
echocardiography were performed on the mice at 30 weeks of age as
described in Materials and Methods (Figure 2C, arrow). HSP70 was
significantly increased in NTG mice by oral administration of GGA
(Figure 2D and E), whereas no obvious induction of small HSPs such
as HSPB8, HSPB1 or HSPB5 was observed. In contrast to NTG
mice, GGA treatment markedly enhanced the induction of HSPB8
a n dH S P B 1i nR 1 2 0 GT Gm i c e( F i g u r e2 Da n dE )w i t has l i g h t
induction of HSP70 (Figure 2D and E). These results suggest that
GGA can profoundly enhance the induction of a discrete subset of
small HSPs in R120G TG mouse hearts.
Effect of GGA on HSPB5 R120G cardiomyopathy
Small HSPs, such as HSPB1 and HSPB8, could be protective in
HSPB5 R120G induced-cellular toxicity [15]. Therefore, we
analyzed hearts and cardiac function with or without GGA
treatment. The heart size in HSPB5 R120G TG were greatly
enlarged relative to NTG (Figure 3A and B). Concomitant with
Figure 3. Effect of long-term GGA treatment on development of cardiomyopathy in HSPB5 R120G TG (R120G TG) mice. (A)
Representative pictures of the hearts in the R120G TG mice at 30 weeks of age. (B) The ratios of heart weight per body weight. Long-term GGA
treatment inhibited hypertrophy in R120G TG mice (n=6–8 mice). (C) Masson’s trichrome stain in the R120G TG mouse heart with or without GGA
treatment (2% GGA). (D) Fractional shortening. Cardiac functional measurement was carried out at 30 weeks of age (n=10–15 mice). (E) Survival
curves. GGA treatment effectively attenuated premature death in the R120G TG mice (n=15–20 mice). (F) Heat shock factor (HSF1) in the hearts.
Localization of HSF1 is shown in heart from R120G TG mice. ***p,0.001 vs. NTG mice and # p,0.05, ## p,0.01, and ### p,0.001 vs. R120G TG
mice with 0% GGA (0% GGA in the R120G TG mice).
doi:10.1371/journal.pone.0005351.g003
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also observed (Figure 3C–E, Table 1). These results imply that
R120G TG mice can recapitulate the DRM pathology, resulting
in eventual heart failure and death as described previously [3,14].
GGA treatment attenuated the development of cardiac hypertro-
phy in R120G TG mice in a dose-dependent manner (Figure 3A
and B). Partial improvements in cardiac function and inhibition of
interstitial fibrosis were also observed (Figure 3C–D, Table 1) as
well as a significant improvement in probability of survival over
time (Figure 3E). Since it is known that protein interaction
between heat shock factor (HSF) and HSP70, as well as nuclear
translocation of HSF is important for HSP induction by GGA
[20], the effect of GGA on HSF1 localization was examined
(Figure 3F). While HSF1 was present in the cytosol of the NTG
hearts, obvious nuclear localization was seen in the R120G TG
hearts with or without GGA treatment (Figure 3F). GGA
Table 1. Echocardiographic parameters.
Body weight (g) LVIDd (mm) LVIDs (mm) LVESV (ml) LVEDV (ml) Ejection Fraction (%)
NTG 27623 . 2 60.2 1.560.1 3.860.6 35668 9 63
R120G TG+0%GGA 29624 . 3 60.1* 3.360.1* 35.863.0* 8264* 5762*
R120G TG+1%GGA 27624 . 0 61.0 2.960.1 26.762.9# 6665# 6163
R120G TG+2%GGA 30623 . 8 61.0# 2.760.1# 20.562.3# 5964# 6662#
NTG 32623 . 5 60.2 1.960.1 6.660.4 45668 5 62
tTA/HSP B8 TG 30623 . 5 60.2 1.860.2 6.861.6 45678 6 62
R120 G TG 30624 . 3 60.1* 3.260.1* 35.463.2* 8264* 5762*
Triple TG 32624 . 0 60.1# 2.860.1# 2362# 6463# 6562#
Values are mean6SEM. N=10–15 in each group.
LVIDd indicates left ventricular internal end-diastolic dimension; LVIDs, left ventricular internal end-systolic dimension; LVESV, left ventricular end-systolic volume;
LVEDV, left ventricular end-systolic volume.
*p,0.05 vs. NTG.
#p,0.05 vs. R120G TG.
doi:10.1371/journal.pone.0005351.t001
Figure 4. Inhibition of aggregate (A–C) and amyloid oligomer formation (D–E) by GGA treatment in HSPB5 R120G TG (R120G TG)
mice at 30 weeks of age. (A) Representative pictures of the immunohistochemistry are shown. The aggregates containing the mutant HSPB5
R120G protein were observed in the R120G TG mice, and long-term GGA treatment reduced the aggregates. (B) Typical picture of the filter assay for
the detection of the aggregates. (C) Quantitative analysis of the aggregates containing the mutant HSPB5 R120G protein (n=4 mice). (D) Effect of
GGA on expression level of the amyloid oligomer. The amyloid oligomer (green) was stained by the anti-oligomer antibody as described in the
Materials and Methods section. To distinguish the cardiomyocytes, cardiac troponin I was stained (red). (E) Quantitative analysis of the amyloid
oligomer. Amyloid oligomer levels were measured by fluorescence intensity. GGA treatment reduced the HSPB5 R120G-induced amyloid oligomer
formation. Values shown are the -fold increase relative to NTG mice, whose value was set to 1. (n=4 mice) *** p,0.001 vs. NTG mice; # p,0.05,
### p,0.001 vs. R120G TG mice.
doi:10.1371/journal.pone.0005351.g004
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oligomer formation in the R120G TG hearts (Figure 4A–E). These
results indicate that long-term GGA treatment can suppress
development of HSPB5 R120G-induced cardiac disease.
HSPB8 can suppress HSPB5 R120G cardiomyopathy in
vivo
To clarify the functional role of HSPB8 induction on the
development of HSPB5 R120G cardiomyopathy and test
sufficiency, we generated a TG mouse, in which HSPB8 is
overexpressed in a cardiac-specific manner using the inducible a-
myosin heavy chain promoter [13] (Figure 5). The expression level
of HSPB8 in tTA/HSPB8 double TG (tTA/HSPB8 TG) mice was
twice the NTG level, while expression of the other HSPs tested
was unchanged (Figure 5A and B). No significant differences in
cardiac function, heart weight, histology or survival rate could be
detected in these mice, suggesting that twice the level of
overexpression of HSPB8 is nontoxic for cardiomyocytes
(Figure 5A–G, Table 1). Next, we crossbred HSPB8 TG mice
with R120G TG mice and generated tTA/HSPB8/R120G triple
TG mice, which overexpress HSPB5 R120G and HSPB8 proteins
in a cardiac-specific manner. The expression level of HSPB8 in
hearts of R120G TG and tTA/HSPB8/R120G triple TG mice
was 1.9- and 3.4-fold that of NTG mice, respectively, while the
other small HSPs including HSPB5 were similar between the
tTA/HSPB8/R120G triple TG mice and the R120G TG mice
(Figure 5A and B). The tTA/HSPB8/R120G triple TG mice
showed decreased heart weight, improved cardiac function and
Figure 5. HSPB8 was overexpressed using tTA/inducible a-myosin heavy chain promoter system as described in Materials and
Methods. (A) Representative Western blots using hearts from tTA/HSPB8 double transgenic (tTA/HSPB8 TG) mice, HSPB5 R120G transgenic (R120G
TG) and tTA/HSPB8/HSPB5 R120G triple transgenic (Triple TG) mice. (B) Quantitative analysis of small HSP levels (n=4 mice). Values are the -fold
increase relative to those in non-transgenic (NTG) mice whose values are arbitrarily set to 1. (C) Representative pictures of R120G TG, tTA/HSPB8 TG
and Triple TG hearts at 30 weeks of age. (D) The ratios of heart weight per body weight. Overexpression of HSPB8 inhibited cardiac enlargement in
R120G TG mice (n=6–8 mice). (E) Masson’s trichrome stain. Overexpression of HSPB8 attenuated the interstitial fibrosis in R120G TG mice. (F)
Fractional shortening assessed by the echocardiogram. Cardiac functional measurements were made at 30 weeks (n=10–15 mice). (G) Survival
curves. Overexpression of HSPB8 effectively attenuated premature death in R120G TG mice (n=15–20 mice). *** p,0.001 vs. NTG mice and #
p,0.05, and ### p,0.0001 vs. the R120G TG.
doi:10.1371/journal.pone.0005351.g005
GGA and Cardiomyopathy
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mice (Figure 5C–F, Table 1). Premature death was completely
suppressed by the overexpression of HSPB8 in R120G TG mice
(Figure 5G). Aggregate accumulation as well as amyloid oligomer
level was reduced as well (Figure 6A–E).
In another set of experiments, we treated tTA/HSPB8/R120G
triple TG mice from 4 weeks to 30 weeks of age with doxycycline
to shut down HSPB8 transgene expression. The levels of HSPB8
were similar between the tTA/HSPB8/R120G triple TG mice
treated with doxycycline and the HSPB5 R120G TG mice
(Figure 7A and B). The levels of aggregates as well as cardiac
hypertrophy were similar between the tTA/HSPB8/R120G triple
TG mice treated with doxycycline and the HSPB5 R120G TG
mice (Figure 7C–F). These results imply that the overexpression of
HSPB8 is critical to suppress the progression of cardiac disease in
HSPB5 R120G TG mice.
Inhibition of apoptotic cell death by GGA treatment or
overexpression of HSPB8
We have shown that apoptotic cell death mediated through
mitochondrial and caspase pathways plays a critical role in disease
progression in HSPB5 R120G cardiomyopathy [18]. We hypoth-
esized that GGA treatment and overexpression of HSPB8 mediate
their effects through reduction in cell death. To test this
hypothesis, we analyzed cytochrome c release from mitochondria,
a process that can initiate the intrinsic apoptotic response.
Cytochrome c was markedly decreased in the mitochondrial
fraction of the R120G TG mouse heart (Figure 8A), and increased
in the cytosol (Figure 8A) and activation of caspase-3 as well as
increased TUNEL-positive cardiomyocyte death was detected in
the R120G TG mouse hearts (Figure 8B–D). Both GGA treatment
and overexpression of HSPB8 resulted in inhibition of cytochrome
c release from mitochondria, decreased activation of caspase-3 and
attenuated TUNEL-positive cardiomyocyte death in R120G TG
mice (Figure 8A–D). These results suggest that GGA treatment
and overexpression of HSPB8 inhibit apoptotic cell death through
mitochondrial and caspase pathways.
Discussion
In our previous study, we found that HSPB5 R120G, which can
cause DRM, led to increased perinuclear aggresome formations
that contain amyloid oligomer [3]. Continuous expression of the
mutant HSPB5 R120G protein was required to sustain high
concentrations of the amyloid oligomer, which correlated with
depressed cardiac function as well as premature lethality [14]. It is
hypothesized that amyloid oligomers can permeabilize cellular
membranes and lipid bilayers, which may represent the primary
toxic mechanism of amyloid pathogenesis [21]. Another previous
study suggests that cellular toxicity induced by the amyloid
oligomer is associated with mitochondrial function as well as
induction of apoptotic cell death by cytochrome c release from
mitochondria [18]. Thus, attenuation of amyloid oligomer
formation might be an effective therapeutic strategy for the
treatment of DRM. Our previous in vitro study showed that
HSPB8 and HSPB1, which can bind to HSPB5 R120G, inhibited
amyloid oligomer formation and reduced cell death in the R120G
transfected cardiomyocytes [15]. In the present study, we extend
these findings to the in vivo level.
Many studies using GGA focused on HSP70 induction
[16,20,22,23,24]. In the present study, induction of HSP70 had
already occurred in the HSPB5 R120G TG mouse hearts and only
modest enhancement of HSP70 expression was observed with long-
termGGAtreatment. These results imply that although the effect of
GGA on HSP70 induction is well characterized, it is not always the
Figure 6. Inhibition of aggregate formation (A–C) and amyloid oligomer formation (D–E) by overexpression of HSPB8 in HSPB5
R120G TG mice (R120G TG) at 30 weeks of age. (A) Representative pictures of the immunohistochemistry are shown. The aggregates
containing the mutant HSPB5 R120G protein are observed in R120G TG mice, and the overexpression of HSPB8 reduced the aggregates in samples
from HSPB8 TG mice (tTA/HSPB8/HSPB5 R120G triple TG; Triple TG). (B) Typical picture of the filter assay for the detection of the aggregates. (C)
Quantitative analysis of the aggregates containing mutant HSPB5 R120G protein (n=4 mice). (D) Effect of HSPB8 overexpression on amyloid oligomer
formation (green). (E) Amyloid oligomer levels were measured by fluorescence intensity. The overexpression of HSPB8 reduced the HSPB5 R120G-
induced amyloid oligomer formation (Triple TG). Values shown are the -fold increase relative to NTG mice, whose value was set to 1 (n=4 mice). To
distinguish the cardiomyocytes, cardiac troponin I was stained (red)(A and D). *** p,0.001 vs. NTG mice; ### p,0.001 vs. R120G TG mice.
doi:10.1371/journal.pone.0005351.g006
GGA and Cardiomyopathy
PLoS ONE | www.plosone.org 8 April 2009 | Volume 4 | Issue 4 | e5351sole basis for the protective effect of GGA. Furthermore,
overexpression of HSP70 failed to rescue the neurodegenerative
disease and reduce aggregate formation in other amyloid-related
neurodegenerative disease models that are caused by a polygluta-
mine repeat [25,26], while GGA treatment was effective in mice
with spinal and bulbar muscular atrophy (SBMA), which is also
caused by a polyglutamine repeat [20]. Thus, HSP70 induction as a
protective mechanism may be cell context dependent particularly as
it relates to GGA treatment. In the model tested here, we found that
long-term treatment with GGA results in HSPB8 induction and a
similar level of overexpression of HSPB8 via transgenic manipula-
tion recapitulates the protective effect of GGA in HSPB5 R120G
cardiomyopathy. We have shown that HSPB8 can directly interact
with HSPB5 R120G and inhibit amyloid oligomer and aggresome
formation[15].HSPB8 interactswith HSPB5 R120Gandfunctions
as a chaperone, assisting in the folding of the mutant protein
[27,28]. The present study confirms that induction of HSPB8 is
beneficial for inhibiting DRM progression and that HSPB8 may
play a critical role in mediating the protective effect of GGA.
HSP70 expression was significantly increased in the hearts of
NTG mice treated with GGA, but there was no obvious induction
in other small HSPs such as HSPB8, HSPB1 and HSPB5. In
contrast to the NTG mouse hearts, small HSPs were induced in
the HSPB5 R120G TG mouse hearts. Similar findings were
observed in a spinal and bulbar muscular atrophy (SBMA) TG
mouse model: oral administration of GGA up-regulated the
expression of HSPs in the central nervous system in the SBMA TG
mice while no induction was detected in NTG mice [20]. The
Figure 7. Effect of doxycycline (DOX) on aggregate formation and heart weight in tTA/HSP B8/R120G triple TG mice (Triple TG) at
30 weeks of age. DOX was administered via drinking water (1g/l) from 4 weeks of age. (A) Representative Western blots using hearts from tTA/
HSPB8 double transgenic (tTA/HSPB8 TG) mice with DOX, HSPB5 R120G transgenic (R120G TG) and tTA/HSPB8/HSPB5 R120G triple transgenic (Triple
TG) mice with DOX. (B) Quantitative analysis of HSPB8 levels (n=4 mice). Values are the -fold increase relative to those in non-transgenic (NTG) mice
whose values are arbitrarily set to 1. (C) Representative pictures of the immunohistochemistry are shown. Green color shows HSPB5 and red color
shows troponin I. (D) Typical picture of the filter assay for the detection of the aggregates. The aggregates containing the mutant HSPB5 R120G
protein are observed in R120G TG mice (No. 4) and triple TG mice with doxycycline (No. 5). (E) Quantitative analysis of aggregates (n=6 mice). Values
are the -fold increase relative to those in NTG mice (No.1) whose values are arbitrarily set to 1. (F) The ratios of heart weight per body weight (n=6
mice). Cardiac enlargement is seen in R120G TG mice (No. 4) and triple TG mice (No. 5) whereas no difference is observed among NTG (No.1), tTA/
HSPB8 TG (No. 2) or tTA/HSPB8 mice with DOX. *** p,0.001 vs. NTG mice; ### p,0.001 vs. tTA/HSPB8 TG mice; aaa p,0.001 vs. R120G TG mice; bb
p,0.01 vs. Triple TG mice.
doi:10.1371/journal.pone.0005351.g007
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expression in HSPB5 R120G TG mice has not been fully
elucidated. Since HSPs were already induced in both the HSPB5
R120G TG mouse hearts and the SBMA TG mouse central
nervous systems, the effect of GGA on HSP induction may be
heightened under conditions of stress. Further studies must address
the effect of GGA on small HSP induction.
Many previous studies using GGA have analyzed the expression
of HSP70 [16,22,23,24]. GGA can directly bind to HSP70, and
this binding results in dissociation between HSP70 and the HSF
complex [24,29,30]. It is hypothesized that the dissociated HSF
from HSP70 can predominately translocate to the nuclei and
activate HSP transcription by binding HSF binding elements
(HSE) in such targets as the HSP70 promoter. Another study
suggests that activation of PKC (translocation of PKCdelta) by
GGA plays a role in mediating HSF translocation [24]. Thus,
these studies imply that the protein interaction between HSF and
HSP70 is important for GGA-mediated HSP induction
[24,29,30]. In mammalian cells, induction of HSP70 requires
activation and nuclear localization of HSF-1 [30,31]. These
Figure 8. TUNEL-positive cardiomyocyte death in HSPB5 R120G TG (R120G TG) mice. (A) Cytochrome c was released from mitochondria
(Mito) into the cytosolic fraction (Cyto) in R120G TG mice while GGA treatment (GGA 2%) and overexpression of HSPB8 inhibited its release. (B)
Immunostaining for activated caspase-3 in sections derived from hearts at 30 weeks of age. Cardiomyocytes were identified by phalloidin staining for
actin (green). Activated caspase-3 (arrowheads) is apparent in the HSPB5 R120G (R120G TG) section. GGA treatment (GGA 2%) and overexpression of
HSPB8 (tTA/HSPB8/HSPB5 R120G triple TG; Triple TG) reduced caspase-3 activation. (C) TUNEL assays in hearts from HSPB5 R120G TG mice at 30
weeks of age. Cardiomyocytes were identified by phalloidin staining for actin (green). Positive signals were apparent only in the HSPB5 R120G-
derived sections and are indicated by an arrow. GGA treatment (GGA 2%) and overexpression of HSPB8 (Triple TG) decreased the TUNEL-positive
signals. (D) Quantification of TUNEL signals. Between 5610
5 nuclei were counted for each sample and the percentage of TUNEL-positive cells were
determined (n=4 mice).
doi:10.1371/journal.pone.0005351.g008
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the hearts of HSPB5 R120G TG mice. However, further
enhancement of HSP70 induction by GGA treatment was modest
in these hearts and HSF1 was already translocated into nuclei in
the R120G TG mice in this study. Although transcriptional
activity of the HSF1 is uncertain, depending on the location of
HSF1 as assessed immunohistochemically, the HSP70-HSF
interaction is not sufficient to explain GGA’s effects completely.
Some previous studies indicate that the protective effect of GGA
may be explained by its modulation of nitric oxide [32,33].
Another study indicates that mitochondria are targets for GGA-
mediated protection against oxidative stress in human monocytes,
independently of HSP70 [34]. These other mechanisms may be
involved in the protective effects of GGA against DRM. Further
studies are needed to elucidate the underlying mechanism of
HSPB8 induction in DRM.
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